A total of 97 patients met inclusion criteria and were treated with biologics. Of these patients, 7 were excluded. Therefore, the study population included 44 patients who received omalizumab, 24 with benralizumab, and 22 with mepolizumab.
Most patients were women (73%), and the mean (SD) age was 55.3 (15) years. After 12 months of treatment, 27.2% of patients had a complete response, which increased to 35.5% at the end of the mean follow-up of 55 months.
The rates of complete response identified were 30.2% in patients treated with omalizumab, 30.4% in patients with benralizumab, and 52.6% in patients with mepolizumab.
Additionally, long-term complete response was associated with better lung function in patients treated with mepolizumab and omalizumab, whereas long-term complete response was associated with fewer previous exacerbations in patients treated with benralizumab.
Furthermore, airflow obstructive pattern identified in 32.5% of cases at 12 months and 34.5% of cases at the end of follow-up was the main cause of not achieving a complete response to treatment.
However, the researchers acknowledged some limitations to the study, including being retrospective in design, a small sample size, and that pulmonary function improvement and lung remodeling seemed to remain an unmet need to reach clinical remission in patients treated with biologics.
Additionally, the researchers believe further research needs to be done to investigate the clinical benefits of switching biologics or the impact of discontinuation of biologics.
“Although previous studies have not targeted treatment-induced remission, in our opinion long-term clinical remission could be included as a therapeutic goal in studies of asthma treatments,” wrote the researchers. “Information on patients with complete response and its maintenance in the long-term is important to improve personalized care.”
Despite these limitations, the researchers believe the study provides evidence that biologics significantly improved clinical outcomes in patients with severe asthma.
This article originally appeared in AJMC.
READ MORE: Respiratory Resource Center
Reference
1. Basagaña M, Martínez-Rivera C, Padró C, et al. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis. Ann Med. 2024;56(1):2317356. doi:10.1080/07853890.2024.2317356